FENC
Fennec Pharmaceuticals Inc
10.60$
-0.1%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 98.1% | 100.0% | 99.9% | 99.2% | 100.0% | 98.2% | 95.0% | |
| 97.3% | 92.4% | 98.8% | 99.5% | 99.3% | 96.5% | 96.6% | 94.1% | 88.3% | 49.4% | 59.3% | 52.4% | |
| 97.3% | 92.4% | 98.8% | 99.5% | 99.3% | 96.5% | 96.6% | 94.1% | 88.3% | 49.4% | 59.3% | 52.4% | |
| – | – | – | – | – | – | – | 0.0% | 5.7% | 32.8% | 28.7% | 33.1% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | 0.0% | 2.1% | 8.0% | 2.4% | 2.2% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 74.2% | 46.2% | 10.1% | 5.8% | 7.1% | 16.1% | 7.5% | 29.6% | 109.5% | 143.3% | 113.1% | 50.0% | |
| 74.2% | 46.2% | 10.1% | 5.8% | 7.1% | 16.1% | 7.5% | 7.4% | 17.1% | 28.1% | 15.4% | 15.0% | |
| 55.6% | 8.0% | 0.8% | 0.6% | – | – | – | 0.1% | – | 0.1% | 0.0% | – | |
| 13.0% | 29.1% | 6.1% | 3.0% | 4.5% | 11.4% | 5.0% | 3.5% | 8.9% | 14.1% | 7.2% | 6.6% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | 22.3% | 92.4% | 115.1% | 43.0% | – | |
| 25.8% | 53.8% | 89.9% | 94.2% | 92.9% | 83.9% | 92.5% | 70.4% | -9.5% | -43.3% | -13.1% | 50.0% | |
| -4,674.3% | -10,945.3% | -2,878.2% | -427.3% | -571.9% | -1,018.2% | -516.1% | -800.8% | -754.3% | -816.1% | -488.8% | -327.3% | |
| 416.1% | 1,062.5% | 321.4% | 52.9% | 82.9% | 140.6% | 75.4% | 116.0% | 97.5% | 98.9% | 60.7% | 40.8% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.